In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo abacavir ("1592") compassionate use program for pediatric AIDS to be launched in June.

Executive Summary

GLAXO ABACAVIR EXPANDED ACCESS PROGRAM IN PEDIATRIC AIDS TO BEGIN IN JUNE, the company told HIV/ AIDS groups in a recent letter. A reverse transcriptase inhibitor, abacavir (1592U89) is in Phase III trials, with an NDA filing expected in 1998. In July, Glaxo Wellcome plans to launch two additional compassionate use programs: for people with severe AIDS Dementia Complex (ADC) and for the adult AIDS population. A broader program is planned for early 1998. The initiatives will run concurrently with controlled clinical trials, the letter states.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel